Description

Retatrutide 20 mg — High-Dose Triple Agonist for Metabolic & Body Composition Research

Retatrutide is a synthetic triple agonist peptide engineered to activate three distinct metabolic receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This 20 mg vial provides a higher peptide quantity per unit for research protocols requiring larger working volumes or extended study durations. Retatrutide has been investigated for its effects on body weight regulation, glycemic control, hepatic lipid metabolism, and energy expenditure.

What It Is

• Class: GLP-1 / GIP / Glucagon triple receptor agonist
• Concept: Engages three complementary metabolic pathways at once, combining the appetite and glucose effects of GLP-1 and GIP with the energy-expenditure and lipolytic effects of glucagon receptor activation.
• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Multi-Receptor Engagement

• Binds and activates GLP-1 receptors on pancreatic β-cells, influencing insulin secretion in a glucose-dependent manner.
• Activates GIP receptors, contributing to insulin response and adipose tissue effects.
• Engages glucagon receptors in hepatic and adipose tissue, supporting increased basal metabolic rate and lipolysis in research models.

Downstream Metabolic Effects

• Research explores changes in body weight, fat mass, and lean mass composition through combined appetite suppression and increased energy expenditure.
• Investigations into hepatic triglyceride content and markers associated with non-alcoholic fatty liver disease (NAFLD).
• Model-dependent effects on HbA1c, fasting glucose, and postprandial glucose handling.
• Interest in cardiovascular risk markers including blood pressure and lipid profile changes.

Selected Research Highlights

• Body Composition Studies: Retatrutide has been examined in trials measuring reductions in body weight and visceral adipose tissue across varying dose ranges, with effects reported to be dose-dependent.
• Metabolic Endpoints: Investigations include changes in glycemic markers, insulin sensitivity, and lipid profiles in subjects with metabolic dysfunction.
• Hepatic Research: Studies have explored Retatrutide’s effects on liver fat content and markers associated with steatohepatitis.
• Comparative Pharmacology: Research has compared triple-agonist mechanisms against single-agonist (GLP-1 only) and dual-agonist (GLP-1/GIP) reference compounds for differential effects on energy balance.

Chemical & Handling Information

• Type: Synthetic triple-agonist peptide
• Backbone: Modified GIP-based sequence with structural modifications that confer balanced activity across three target receptors (exact sequence per lot specification)
• Appearance: White to off-white lyophilized powder
• Solubility: Reconstitutes readily in bacteriostatic water or sterile saline for laboratory preparation

Specifications

• Peptide: Retatrutide
• Amount: 20 mg per vial
• Form: Lyophilized powder
• Purity: ≥99% (HPLC); COA per lot available
• Packaging: Sealed glass vials with rubber stopper and aluminum crimp seal, suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place, protected from light.
• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, in accordance with standard laboratory SOPs.
• After reconstitution, store at 2–8 °C for short-term laboratory use (typically up to 30 days).
• For long-term storage of reconstituted material, aliquot and freeze at −20 °C or below.
• Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Use Disclaimer

This product is sold strictly for laboratory research use only. Not intended for human or animal consumption. Not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. Customers are solely responsible for the lawful handling, storage, and use of this product in accordance with all applicable laws and regulations.